Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07238322 · ClinicalTrials.gov registry record
[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes
A clinical trial of Glioma and Brain Neoplasms, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
- Active
- Registry status
- 400
- Enrollment target
- 4
- Study locations
NCT07238322 is a study of Glioma and Brain Neoplasms that is active but no longer recruiting, run by Telix Pharmaceuticals (Innovations) Pty Limited. The registered enrollment target is 400 participants, above the 205-participant average among 87 other Glioma trials with a reported enrollment target (95% higher). The trial reports 4 study locations across 2 states.
The verdict
NCT07238322, a study of Glioma and Brain Neoplasms, is active but no longer recruiting, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
- ACTIVE NOT RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is designed to prospectively analyze \[18F\]FET PET image data obtained retrospectively in the routine clinical care of glioma patients. The study will analyse the data from participants with grade (1-4) glioma after primary treatment according to local clinical practice and with suspicion of progression/recurrence on magnetic resonance imaging (MRI).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST 18F(FET)PET
Study Locations (4)
Other
- University Hospital Essen - Essen
- Universityhospital Tuebingen - Tübingen
- The University Medical Center Utrecht - Utrecht
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2025-09-22 |
| Est. Completion | 2026-02-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07238322
The ClinicalTrials.gov registry entry for NCT07238322 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 205-participant average among 87 other Glioma trials with a reported enrollment target (95% higher). The listed sponsor is Telix Pharmaceuticals (Innovations) Pty Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Glioma appearing as the primary indexed condition, and to 1 intervention - of which 18F(FET)PET is the first listed.
NCT07238322 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Other, California.
Frequently Asked Questions
What is clinical trial NCT07238322 about?
NCT07238322 is a clinical study titled "[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes". This study is designed to prospectively analyze \[18F\]FET PET image data obtained retrospectively in the routine clinical care of glioma patients. The study will analyse the data from participants with grade (1-4) glioma after primary treatment according to local clinical practice and with suspicio...
What is the current status of trial NCT07238322?
This trial is currently active not recruiting. The enrollment target is 400 participants. The study started on 2025-09-22. Estimated completion is 2026-02-23.
What conditions does trial NCT07238322 study?
This clinical trial studies the following conditions: Glioma, Brain Neoplasms, Retrospective Study.
What interventions are being tested in trial NCT07238322?
The interventions under investigation include: 18F(FET)PET (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07238322?
This trial is sponsored by Telix Pharmaceuticals (Innovations) Pty Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07238322 being conducted?
This trial has 4 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
RECRUITING · Phase 2
-
Tumor Treating Fields for the Treatment of Brainstem Gliomas
RECRUITING · NA
-
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
RECRUITING · Phase 4
-
Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks
RECRUITING
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.